首页 > 市场调查报告书 > 製药

癌症

市场调查报告书

商品编码

1544692

胃癌治疗市场、机会、成长动力、产业趋势分析与预测，2024-2032

Stomach Cancer Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年07月12日 | 出版商:

Global Market Insights Inc. | 英文 281 Pages | 商品交期: 2-3个工作天内

价格

简介目录

由于研究和临床试验的加强，预计 2024 年至 2032 年胃癌治疗市场的复合年增长率将达到 13.5%。

研究人员正在研究新的疗法和治疗方法，以改善胃癌患者的预后。临床试验处于最前沿，评估突破性药物、标靶治疗和个人化医疗策略，所有这些都旨在增强疗效，同时最大限度地减少副作用。这些试验也探索创新的治疗组合和先进的方法，以製定更有效和客製化的治疗方案。例如，2023年11月，美国FDA扩大了Pembrolizumab的适用范围，批准其用于胃癌和食道交界癌，从而为这些患者引入了新的治疗途径。

整个市场分为类型、适应症、药物类别、给药途径、配销通路和地区。

就类型而言，到 2032 年，由于增强人体对癌细胞的免疫反应的迫切需要，胃癌治疗市场的免疫治疗领域将经历强劲增长。研究人员正在积极开发和评估从检查点抑制剂到 CAR-T 细胞疗法的多种免疫治疗方式，所有这些都是为了提高治疗效果。免疫疗法的机制围绕着精确定位癌细胞中的特定蛋白质或调整免疫细胞以获得更强大的肿瘤攻击。此外，正在进行的研究正在深入研究联合疗法和客製化策略，以最大限度地提高疗效，同时减少副作用。

按配销通路，专业药房和零售药房领域的胃癌治疗行业价值预计将在 2024 年至 2032 年期间上升。这些药房不仅配发专门的药物，例如标靶药物和免疫疗法，还提供个人化的患者咨询。此外，专业药局在管理复杂的治疗方面发挥关键作用，确保患者接受药物治疗，同时提供必要的监测和依从性支持。

从地区来看，在医疗保健投资不断增加的推动下，亚太地区胃癌治疗市场规模预计将在 2024 年至 2032 年间实现强劲成长。这些投资不仅支持研发，还为突破性疗法铺平道路，包括标靶治疗和免疫疗法。此外，这些财政刺激正在促进临床试验的扩大，并增加患者获得最先进治疗的机会。作为这些努力的结晶，该地区预计将有更完善的治疗方法、改善的患者治疗效果以及更广泛的有效治疗方法。

产业生态系统分析
产业影响力
- 成长动力
  - 胃癌盛行率增加
  - 诊断技术的进步
  - 标靶治疗的开发
  - 提高认识和筛检计划
- 产业陷阱与挑战
  - 治疗费用高
  - 与癌症治疗相关的副作用和安全性问题
成长潜力分析
监管环境
技术景观
- 核心技术
- 邻近技术
2023 年定价分析
- 按地区
- 按关键人物
未来市场趋势
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按类型，2021 - 2032

主要趋势
化疗
免疫治疗
标靶治疗

第 6 章：市场估计与预测：按指标划分，2021 - 2032 年

主要趋势
胃癌/胃食道结合部癌
胃肠道间质瘤

第 7 章：市场估计与预测：按药物类别，2021 - 2032 年

主要趋势
PD-1/PD-L1抑制剂
HER2拮抗剂
VEGFR2拮抗剂
其他药物类别

第 8 章：市场估计与预测：按管理途径，2021 - 2032 年

主要趋势
口服
可注射

第 9 章：市场估计与预测：按配销通路划分，2021 - 2032 年

主要趋势
医院药房
专业药局和零售药局
其他分销管道

第 10 章：市场估计与预测：按地区，2021 - 2032

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 11 章：公司简介

AstraZeneca PLC
Bristol Myers Squibb Company
Bayer AG
Biocon Limited
Celltrion Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Ipsen Pharma
Merck and Co., Inc.
Novartis AG
Otsuka Holdings Co., Ltd.
Pfizer Inc.
Samsung Biologics Co., Ltd.
Teva Pharmaceutical Industries Ltd.
Viatris Inc.

简介目录

Product Code: 10227

Stomach Cancer Treatment Market is projected to record a 13.5% CAGR from 2024 to 2032, driven by an intensified emphasis on research and clinical trials.

Researchers are delving into novel therapies and treatment methodologies to bolster outcomes for stomach cancer patients. Clinical trials are at the forefront, evaluating groundbreaking drugs, targeted therapies, and personalized medicine strategies, all aimed at amplifying efficacy while minimizing side effects. These trials are also probing into innovative therapy combinations and advanced methodologies to curate more effective and customized treatment regimens. For example, in November 2023, the U.S. FDA broadened the scope of Pembrolizumab, approving it for stomach and esophageal junction cancer, thereby introducing a fresh therapeutic avenue for these patients.

The overall market is segregated into type, indication, drug class, route of administration, distribution channel, and region.

In terms of type, the immunotherapy segment in the stomach cancer treatment market will experience robust growth by 2032 led by the escalating imperative to bolster the body's immune response against cancer cells. Researchers are actively developing and evaluating diverse immunotherapy modalities, from checkpoint inhibitors to CAR-T cell therapy, all to enhance treatment outcomes. The mechanism of immunotherapy revolves around pinpointing specific proteins in cancer cells or tweaking immune cells for a more robust tumor attack. Furthermore, ongoing investigations are delving into combination therapies and tailored strategies to maximize efficacy while curtailing side effects.

By distribution channel, the stomach cancer treatment industry value from the specialty and retail pharmacies segment is projected to rise from 2024 to 2032. This surge is attributed to the increasing demand for a comprehensive range of therapies and ancillary support services. These pharmacies are not only dispensing specialized medications, such as targeted and immunotherapies but are also providing personalized patient counseling. Moreover, specialty pharmacies play a pivotal role in managing intricate treatments, ensuring patients receive their medications whilst offering essential monitoring and adherence support.

Regionally, the Asia Pacific stomach cancer treatment market size is projected to accrue robust growth between 2024 and 2032, fueled by rising healthcare investments. These investments are not just bolstering R and D but are also paving the way for groundbreaking therapies, including targeted treatments and immunotherapy. Furthermore, these financial boosts are facilitating the broadening of clinical trials and enhancing patient access to state-of-the-art treatments. As a culmination of these efforts, the region anticipates refined treatment methodologies, improved patient outcomes, and a wider reach of effective therapies.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of stomach cancer
  - 3.2.1.2 Advancements in diagnostic techniques
  - 3.2.1.3 Development of targeted therapies
  - 3.2.1.4 Rising awareness and screening programs
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of treatment
  - 3.2.2.2 Side effects and safety concerns associated with cancer therapies
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
- 3.5.1 Core technologies
- 3.5.2 Adjacent technologies
3.6 Pricing analysis, 2023
- 3.6.1 By region
- 3.6.2 By key player
3.7 Future market trends
3.8 Porter's analysis
3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Chemotherapy
5.3 Immunotherapy
5.4 Targeted therapy

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Gastric cancer /gastroesophageal junction cancer
6.3 Gastrointestinal stromal tumors

Chapter 7 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 PD-1/PD-L1 inhibitors
7.3 HER2 antagonists
7.4 VEGFR2 antagonists
7.5 Other drug classes

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Oral
8.3 Injectable

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 Hospital pharmacies
9.3 Specialty and retail pharmacies
9.4 Other distribution channels

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Netherlands
- 10.3.7 Rest of Europe
10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Argentina
- 10.5.4 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 UAE
- 10.6.4 Rest of Middle East and Africa